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Abstract
This review examines the impact of gender affirming hormone therapy used in the transgendered and non-binary
populations on cardiovascular outcomes and surrogate markers of cardiovascular health. Current evidence suggests
that hormonal therapy for transgendered women decreases or is neutral regarding myocardial infarction risk. There is an
increased incidence of venous thromboembolism (VTE), but newer studies suggest that the risk is significantly lower
than previously described. For transgendered men, there appears to be an adverse effect on lipid parameters but this
does not translate into an increased risk of cardiovascular disease above that of general male population. In all trans-
gendered people, risk factor interventions such as smoking cessation, weight management and treatment of co-morbid
conditions are important in optimising cardiovascular health. The effect of gender affirming hormonal therapy in trans-
gendered people is difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods
of observation and the influence of confounding factors such as the historical use of less physiological, oestrogens such
as conjugated equine oestrogen and ethinylestradiol which are more pro-thrombotic than the 17b oestradiol that is used
in modern practice.
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Introduction
Hormone replacement therapy for the majority of
transpeople is an important part of their transition pro-
cess. It is known that sex steroid therapy is associated
with cardiovascular risk1–6 but there is poor quality
evidence of the extent of this risk in the transgendered
population. Cardiovascular risk in this population has
been examined by meta-analyses;7–9 however, the liter-
ature has been extended with the recent publication of
further large studies looking at cardiovascular out-
comes in transgendered people, both in the USA10–12
and Europe.13
This review will examine the current evidence on the
impact of gender affirming hormonal therapy in the
binary transgendered population, on cardiovascular
health and surrogate markers of cardiovascular risk
such as lipid profile and thrombotic risk. It will also
put these findings in the context of the recent studies
and also discuss non-hormonal factors that may
contribute to adverse cardiovascular outcomes in
this population.
Methods
A literature search of the current English language lit-
erature was made using the Pub Med database using
key words to identify articles relating to cardiovascular
health in transgendered people. Key words were
transgender, transgendered, transsexual, transman,
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transmen, transwoman, transwomen, non-binary,
myocardial infarction, MI, thromboembolism, pulmo-
nary embolism, deep venous thrombosis, TE, DVT,
PE, stroke, cardiovascular, lipid, metabolic, and
meta-analysis.
Where studies were included in a meta-analysis these
data were used to give an overview of the effect of
gender affirming hormone treatment on an outcome.
Cardiovascular disease and gender
Cardiovascular disease has a major impact on mortal-
ity. In the 20th century, it was the major cause of mor-
tality and has only recently been overtaken by
malignancy as the leading cause of death in the
UK.14 The risk factors for developing cardiovascular
disease have long been divided into modifiable and
non-modifiable factors. One of the previously non-
modifiable risk factors was gender. There has been
and extensive literature on the gender differences in
cardiovascular risk,15,16 which have usually been attrib-
uted to the difference in hormonal mileu between males
and females.
Gender terminology and
gender dysphoria
People who remain in the gender role they were
assigned at birth are termed cisgendered women
(a person who was birth assigned female who remains
in a female gender role) and cisgendered men (a person
who was birth assigned male who remains in a male
gender role). An increasing number of people are ques-
tioning the gender they were assigned at birth which is
termed gender nonconformity. Many of these people
decide to change their social gender role to one that
is more concordant with their internal sense of
gender, the majority of individuals make a binary tran-
sition from one gender role to a role that would be
viewed as the opposite gender role (from birth assigned
male to female; a transgendered woman or from birth
assigned female to male; a transgendered man) and a
smaller number of people transition to a gender role
that is not defined by male or female (non-binary). The
majority of people who transition gender role use
gender affirming hormonal therapy to achieve the sec-
ondary sexual characteristics of their desired gender
and so their hormone mileu is different to their birth
assigned gender.
Gender dysphoria is not a rare condition with an
impression of rising incidence. Previous estimates of
the incidence ranged between 1:74401 and 1:30,000
for birth assigned males and 1:31,153 to 1:10,000 for
birth assigned females.17 A meta-analysis estimated the
prevalence to be 6.8/100 000 for transgendered women
and 2.6/100,000 for transgendered men.18 More up-to-
date studies suggest that the incidence is higher, with
0.5–1.3% of birth-assigned males and 0.4–1.2% birth-
assigned females identify as a transgendered person.19
A recent study suggested that approximately 10% of
people attending a large single centre gender clinical
have a non-binary gender identity.20 The transgendered
population is growing, cardiovascular death has been
identified as a significant cause of mortality in this pop-
ulation,10,12,21–24 and so its management is part of main
stream medicine, and it is not limited to special-
ist centres.
Cardiovascular risks and endogenous
sex steroids
It has been observed across many study populations
that males have higher cardiovascular mortality than
females certainly until menopause.15,16 After meno-
pause, female cardiovascular mortality increases with
advancing age25,26 and so it is argued that oestrogen is
cardio-protective and testosterone is atherogenic. It is
known that endogenous ovarian hormone production
protects cisgendered women from cardiovascular dis-
ease.27,28 Women with early menopause before the
age of 45, either naturally28 or surgically induced,27
are at higher cardiovascular risk compared to women
who cease ovarian function later [RR 1.19 (95 CI 1.08–
1.31)] and this is mainly due to coronary heart disease
mortality [RR1.11 (95% CI: 1.03–1.2)]. The role of
high androgens levels in the development of cardiovas-
cular disease cisgendered women is less clear. While it is
known that high endogenous testosterone is associated
with increased cardiovascular risk factors including
increased intimal thickness, increased coronary plaques
and increased arterial thickness,29 an association
between androgen levels and cardiovascular events
could not be established in a 10-year follow-up
study.30 The complicating factor here is that the com-
monest cause of hyperandrogenism in females is poly-
cystic ovarian syndrome which may be acting as a
confounder.29
In cisgendered males, it is known that hypogonad-
ism is also associated with increased mortality.31 Men
who have a testosterone level in the lower tertile have
been shown to have a mortality nearly twice that of
men with testosterone levels in the upper tertile over
eight years (hazard ratio (HR) 1.88; 95% CI: 1.34–2.63;
p< 0.001).32 A meta-analysis of hypogonadism in
males confirmed that low testosterone and also high
oestradiol levels in males are associated with increased
cardiovascular disease (HR 0.837(0.823–0.852) for each
nmol/L increment of testosterone; p< 0.0001) and
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(HR 1.002 (1.003–1.004) for each pmol/L increment of
E2; p< 0.0001).
Physiologically it appears that abnormally low
endogenous production of sex steroids of the birth-
assigned gender and the increased levels of sex steroid
levels of the opposite gender are associated with higher
levels of cardiovascular disease.
Cardiovascular risks and exogenous sex
steroids therapy (HRT)
Cisgendered females
The data on the effects of exogenous oestrogen therapy
on cardiovascular events in females comes mainly from
trials looking at postmenopausal HRT. The WHI trial
in postmenopausal women was constructed on the
premise that giving oestrogen to postmenopausal
women would restore their cardiovascular portection;33
however, the trial demonstrated an increase in cardio-
vascular events which lead to its premature termina-
tion. For all cardiovascular events, hazard ratios were
increased at 1.13 (95% CI: 1.02–1.25) for the conjugat-
ed equine oestrogen (CEE)þmedroxyprogesterone
acetate (MPA) arm of the trial. After adjusting for
multiple analyses the hazard ratios for stroke, total
myocardial infarction (MI), coronary artery interven-
tion and cardiovascular deaths were not increased;
however, there was increased risk of thromboembolic
events that remained at 2.11 (95% CI: 1.26–3.55).
A subsequent trial looking at the effect of CEE
alone in hysterectomised females34 found the hazard
ratio for all cardiovascular events was still increased
to 1.11 (95% CI: 1.01–1.22) but this was shown to be
age dependent; the hazard ratios for MI increased
by decade of age (0.55 for 50–59 years, 0.95 for
60–69 years and 1.24 for 70–79 years). These data sug-
gest that the use of oestrogen without progestin given
to females at an earlier age within 10 years of meno-
pause results in the least impact on cardiovascu-
lar events.
Further meta-analysis of 23 randomised control
trials of women receiving HRT again demonstrated a
32% reduction in cardiovascular events;35 these data
suggest that, providing there is not a significant time
without sex steroid exposure, oestrogen HRT can
maintain cardiovascular health. Even though high
endogenous production of testosterone is associated
with increase in markers of cardiovascular risk,29 the
use of therapeutic testosterone replacement in women
has not demonstrated any adverse impact on cardio-
vascular health, suggesting it is safe when doses
are given to achieve testosterone values in the
female range.36,37
Cisgendered males
The treatment of hypogonadism in males with testos-
terone therapy is associated with varying results with
regards to cardiovascular safety. Some have advocated
transdermal replacement as a more physiological
route.38 There have been several meta-analyses and
reviews on this topic; six out of seven of these did not
demonstrate any increase in cardiovascular events.
These data have been reviewed in the Lancet with
summary estimates demonstrating no significant
association between exogenous testosterone and car-
diovascular events ranging from [RR 1.07–1.82].39
There has, however, been controversy about the use
of testosterone in elderly men with three trials suggest-
ing there is an increase in cardiovascular risk.4–6 In the
first trial of 209 elderly men, the trial was stopped pre-
maturely as there was a 5.8 fold (95% CI: 2.0–16.8)
increased adjusted odds ratio of cardiovascular-
related events. This trial, however, was criticised as
the dose of testosterone used (100mg topical gel) was
extremely high, and it is double a standard hormone
replacement dose. In an elderly group of men, it is per-
haps not surprising that adverse events occurred.
Indeed there was a 3% increase in haematocrit which
may have increased plasma viscosity and contributed
to this increase in cardiovascular events.5
The second study reported that testosterone replace-
ment therapy resulted in an increased risk of MI within
90 days of receiving a testosterone prescription in men
65 years old [odds ratio 2.2] and those <65 years with
pre-existing heart disease, [odds ratios 2.9].4
In the third study, men with hypogonadism who
underwent coronary angiography and were replaced
with testosterone had an increase in adverse outcomes
when using a composite endpoint of myocardial infarc-
tion, stroke and death. (HR 1.299 95% CI: 1.04–1.58).6
This study was, however, criticised as the biological
effects of testosterone therapy were not reported
and only 1:5 of the testosterone prescriptions
were ever filled suggesting the hypogonadism was not
corrected.40
Other studied contradict these data. Testosterone
replacement to physiological levels in hypogonadal
men resulted in an improvement in endothelial function
and arterial stiffness.29 An extensive meta-analysis of
testosterone therapy for hypogonadism in men did not
demonstrate any effect of testosterone therapy on all-
cause mortality (OR 1.12 95% CI: 0.7–1.81), risk for
MI (OR 1.0.91 95% CI (0.29–2.82)), or need for
coronary artery vein grafting (OR 1.35 95% CI
(0.26–6.98)), suggesting that on balance testosterone
therapy with the aim of replacement to the normal
male range is safe.
Seal 3
Transgendered women
Oestrogen therapy and androgen suppression in trans-
gendered females simultaneously has a positive and
negative effect on cardiovascular risk factors. The met-
abolic effects of oestrogen therapy are centred around
alteration in liver function and the effects of oestrogen
on lipid parameters. There appears to be a decrease in
hepatic lipase activity by 64% and of lipoprotein lipase
by 23%.8 Hepatic lipase decreases HDL-cholesterol
levels, by catalysing the hydrolysis of triacylglyceride
which results in the conversion of lipid-enriched HDL 2
particles to lipid-poor HDL 3 particles; it also increases
the formation of small, dense LDL particles both of
which are highly atherogenic. Reducing the levels of
hepatic lipase may reduce the formation of these ath-
erogenic lipid particles.
Cross-sectional studies, however, suggest that oes-
trogen has a positive effect on plasma lipids with
higher HDL þ0.2mmol/L (6mg/dl)41 and 0.16mmol/
L (6mg/dl)42 and lower LDL as the LDL-C level was
statistically significantly lower in oestrogen treated
transgendered female group (5.71mmol/L; 95% CI:
5.96–5.44mmol/L; I2¼ 0%) (220.3mg/dL; 95% CI:
230.7–210.0mg/dL; I2¼ 0%).8 There was no change
in other lipid parameters. These studies have small par-
ticipant numbers making the reliability of the find-
ings uncertain.
The effect of oestrogen treatment in transgendered
women has been described in 3 meta-anlyses.7,9,43 The
use of oestrogen therapy in transgendered females
showed no statistically significant difference in serum
LDL-C, HDL-C, and total cholesterol levels but there
was an increase in plasma triglyceride levels after
24months 0.360mmol/L; (95% CI: 0.04–0.67mmol/
L) (31.9mg/dL; 95% CI: 3.9–59.9mg/dL).9
Body composition also changes,44 there is a signifi-
cant increase in body weight (þ3%; 95% CI: þ2%
toþ 5%, p< 0.001) and total body fat (þ28%; 95%
CI: þ24% to þ32%, p< 0.001). At the same time
there is a reduction in lean body mass 3% (95%
CI: 4% to 2%, p< 0.001).45 Gender affirming hor-
mone therapy has also been shown to increase visceral
fat.46 These changes in body composition would be
expected to have a negative impact on cardiovascu-
lar risk.
In a study by Elbers et al, employing euglycaemic
clamping, insulin sensitivity appeared to be reduced (by
33%) with a commitment increase in insulin levels (by
50%). Fasting glucose however appeared not to be
affected.8 Other studies have demonstrated no change
in either fasting insulin levels, HOMA-IR or fasting
glucose levels.43,47,48
There are differing reports on the effect of gender
affirming hormonal therapy in blood pressure in
transgendered females.24 In one large cohort study of
247 individuals oestrogen had no effect on blood pre-
sure49 but in another there was a significant increase of
systolic blood pressure by 7.2mmHg and diastolic
blood pressure of 5.7mmHg.8
Elevated plasma level of total homocysteine had
been shown to be an independent risk factor indepen-
dent for CVD.50–52 Total homocysteine levels vary
between the sexes; the levels are approximately
10–15% lower in women.53 Oestrogen therapy in trans-
gendered females reduced plasma homocysteine levels
8.2mmol/L to 5.7mmol/L (p¼ 0.001);54 this effect is
independent of the route of administration of oestro-
gen,55 This may have a beneficial effect on cardiovas-
cular risks.
Oestrogens alter prothrombotic and inflammatory
markers in transgendered women that may have a
role in cardiovascular disease. It as has been demon-
strated that oral ethinylestradiol in combination with
cyproterone acetate but not transdermal 17Beta oestra-
diol increases CRP56 and decreases tissue plasminogen
activator.57 Other studies have however shown no
effect on CRP58 and so the impact of oestrogen therapy
on prothrombotic changes is unclear. It is of note how-
ever that one of the long term outcome studies suggest
that the increase in cardiovascular risk was limited to
current users of ethinylestradiol22 and the finding that
ethinylestradiol promotes a more prothrombotic mileu
would provide a possible explanation for this result.
The current literature demonstrates that oestrogen
therapy in transgendered females can result in a mix of
changes to physiological parameters. Some increase
cardiovascular risk; increased body fat, increased
weight, increased visceral fat, reduced lean mass, pro-
thrombotic blood changes, and higher triglyceride.
Others decrease cardiovascular risk such as reduced
LDL cholesterol and increases plasma homocysteine
levels. With studies showing an increased rate of
stroke10,13 and thromboembolism9,10,13 it is likely that
the pro-atherogenic changes predominate.
Transgendered men
There are significant gender differences in lipid param-
eters, with males having higher total cholesterol, LDL
cholesterol and triglyceride, with lower plasma HDL
cholesterol. As expected, testosterone therapy in trans-
men adversely alters their lipid parameters. A recent
meta-analysis of the available data demonstrated
there was no change in total cholesterol or LDL cho-
lesterol but there was a minor increase in triglyceride
(0.35 [CI 0.09–0.62] mmol/L) and a decrease in plasma
HDL levels(0.73[CI 0.3 to 0.02] mmol/L), both of
which are pro-atherogenic.7 A more recent meta-
analysis showed that the changes in lipid parameters
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were progressive with time over 24months so that by
24months of testosterone therapy TG levels were
higher (þ0.24mmol/L; 95% CI: 0–0.48mmol/L)
(þ21.4mg/dL; 95% CI: 0.1–42.6mg/dL) compared
with baseline; the serum LDL-C level showed a statis-
tically significant increase (þ0.46mg/dL; 95% CI: 0.1–
0.83mg/dL) (þ17.8mg/dL; 95% CI: 3.5–32.1mg/dL).
HDL-C level decreased significantly (0.21mg/dL;
95% CI: 0.34 to 0.1mg/dL) (8.5mg/dL; 95%
CI: 13.0 to 3.9mg/dL). Total serum cholesterol
level did not show a statistically significant change.
With regards to body composition, there is an
increase in weight in transgendered men treated with
testosterone of þ3% (95% CI: 2%; 4%, p< 0.001) but
this is accompanied by a decrease in total body fat of
9% (95% CI: 12%; 7%, p< 0.001) and an
increase in total lean body mass of þ10% (95% CI:
9%; 11%, p< 0.001).45 On balance, this would be a
positive change for metabolic risk.
In transgendered men, testosterone therapy has no
effect on fasting glucose, fasting insulin or glucose uti-
lisation.8 Studies are contradictory with regards to tes-
tosterone’s effect on blood pressure in transgendered
males. Six studies assessed effects testosterone therapy
on blood pressure levels in transgendered men.59 In one
study, there was an increase in both systolic and dia-
stolic blood pressure;60 in two studies there was an
increase only in systolic blood pressure47,61 and in
two others no significant changes were found.41,49 In
another study, there was a decrease in systolic and dia-
stolic blood pressure levels.62
Testosterone therapy increases plasma homocysteine
levels in transgendered men54 7.7mmol/L to 9.0mmol/
L (p <0.005) which could have a negative impact on
cardiovascular risk.
It is interesting that these changes in lipid profile do
not appear to translate into an alteration in cardiovas-
cular risk, as there is no increase in cardiovascular mor-
tality in treated transmen; indeed one study suggested
the MI rate is approximately one-third of that expected
in the general male population.63 These findings have
been confirmed in long-term follow-up studies where
the standard mortality ratio for transmen is not differ-
ent from the general population.22
Other risk factors
The metabolic factors for cardiovascular disease other
risk factors can have a significant effect in the trans-
gendered population.
Smoking
Smoking is an important risk factor for cardiovascular
events and tobacco use has been demonstrated to be
high in the transgendered population. The incidence of
smoking in the reports series varies from 15%10 to
63.5%64 in transgendered women and 18%10 to
74.4%64 in transgendered men. Smoking is such a pow-
erful co-factor in cardiovascular disease that it may
represent a considerable confounder when looking at
the cardiovascular risk in transgendered people.
It is interesting that the rate of smoking in transgen-
dered men is higher than that of transgendered women
and yet cardiovascular mortality does not seem to be
impacted. In two large series, the rates of MI and
stroke in transgendered men are not higher than
either birth-assigned females or birth-assigned
males.10,13 In another series of 816 transgendered
people, the MI rate for transgendered men was one-
third that of the general population (SIR 0.05 [0.24–
0.91]),63 despite a high rate of tobacco use at 43–46%.13
More recently, however, a large community-based
study of 1.4 million people suggests that smoking
rates in transgendered men and women were higher
than the cisgendered population (smoking rate trans-
gendered men 19.3%, transgendered women 20.3%,
cisgendered men 18.6%, cisgendered women 14.4%)
and here MI rates were higher in transgendered men
compared to cisgendered men (OR 2.53 95% CI: 1.14–
5.63) and cisgendered women (OR 4.90 95% CI:
2.21–10.90).
HIV infection
The incidence of HIV infection in the transgendered
female population appears to be increased compared
to the general population.63 It is has been estimated
that just under a third of transgendered women in the
USA may be seropositive.65 A systematic review which
looked at 39 studies suggested a global HIV prevalence
rate of 19.1% in transgendered women.66 Interestingly,
in this review a much higher HIV burden was found in
transgendered women of colour, Hispanic 49.6% and
African American transgendered women 48.1%.com-
pared to Caucasian transgendered women at 3.5%.
As ethnic origin is a cardiovascular risk factor per se,
this could mean transgendered women living with HIV
have a very high cardiovascular risk.
The association between HIV infection and cardio-
vascular disease is caused by a combination of tradi-
tional risk (e.g. smoking, diabetes, lipid abnormalities),
disease-specific risk factors (e.g. chronic inflammatory
response and lipoprotein-a levels), the effect of antire-
troviral agents, the virus itself and consequences of the
immune response. Coronary artery disease is one of the
leading causes of death in HIV-infected patients.67
One study examined the incidence of coronary risk
factors in transgendered females compared to a cisgen-
dered male control group and found that there were no
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difference in the incidence of cardiovascular risk fac-
tors between the groups.68 They did, however, note
that the transgendered female group did have subopti-
mal HIV control. This heightened immune activation
may be a mechanism by which accelerated cardiovas-
cular disease can occur.
None of the outcome studies in transgendered
people so far have commented on the incidence of
HIV seropositivity in the reported populations and so
cannot be excluded as a cofactor increasing cardiovas-
cular disease incidence.
Stress
Psychological distress is a well-established CVD risk
factor, as it is believed to result in atherosclerosis by
immune dysfunction and maladaptive metabolic
responses.69 Transgendered people are known to
suffer from minority stress.70 Stigmatisation which is
experienced by people in this community enhances dis-
tress via unhealthy coping mechanisms such as
concealment.70
In the US transgender survey, 39% of respondents
reported severe psychological distress. This figure is
eight times higher than the general population.70 It
known that stressful events, chronic stress or repeated
acute stress places people at a higher cardiovascular
risk.69 Undertaking treatment for gender dysphoria
has been shown to successfully reduce stress, improve
quality of life and also to reduce tobacco use.71,72 These
measures may obviate some of the cardiovascular risk
associated with gender affirming hormonal therapy in
the transgendered population.
Cardiovascular outcomes in
transgendered people
Cardiovascular mortality
Long-term outcome studies have demonstrated that
mortality is increased in the transgendered popula-
tion.21,22 Although the major causes of death in these
studies appeared to be from suicide, complications
related to HIV and malignancies cardiovascular risk
was also raised in both these studies.21,22 The first
study was a population-based matched cohort study
in Sweden including 324 participants with an average
follow-up of 11.4 years and it demonstrates a HR of 2.5
(1.2–5.3) for death by cardiovascular disease. This
study is of limited use in dissecting the cause of this
mortality, as it was not stratified for gender, hormone
type used or smoking status. A single-centre cohort
observational study of 996 participants with an average
follow-up of 18.5 years, reported that the standard
mortality ratio was only raised in the transgendered
female population (SMR 1.51(95% CI: 1.47–1.55)
and not the transgendered male population (SMR
1.12 (95% CI: 0.87–1.42). These data suggest that
increased cardiovascular mortality exist in the trans-
gendered population. However, this increase in cardio-
vascular morbidity is limited to the transgendered
female population.
Myocardial infarction (MI)
In the Asscheman cohort study, ischemic heart disease
was the cause of death in 18 subjects (SMR 1.64; 95%
CI: 1.43–1.87).22 These findings have been repeated in
the USA with data from the Behavioural Risk Factor
Surveillance System, with a population of 691 trans-
gendered people. The adjusted odds ratio for MI was
increased to 1.82 (95% CI: 1.22–2.72) but the study did
not stratify the data by birth assigned gender.11
In contrast, other studies have not shown an
increase in myocardial infarction; in a population of
352 transgendered people with 7.4 years of follow-up,
again there was no significant increase in the incidence
of MI compared to control men, although the rate was
increased compared to control women (18.7/1000
(compared to 12.5/1000 men p NS and 0/1000 women
p¼ 0.001). In another shorter study, the rate of MI
was half that expected compared to birth assigned
males (SIR 0.5 (95% CI: 0.24–0.91)).
A large electronic record cohort study of 4960 trans-
gendered people with four years of follow-up demon-
strated no increase in MI compared to reference males
or females (HR 1.0 (95% CI: 0.3–3.2 compared to
males; HR 2.4 95% CI: 0.6–9.4)).
Similar findings occurred in a large cohort study in
Holland of 6793 participants with mean follow-up of
9.07 years. This study reported SIR for MI of 0.79
(95% CI: 0.57–1.11 compared to cisgendered males)
and 2.64 (95% CI: 1.81–3.72 compared to cisgendered
females p< 0.01).13
A very recent study from the USA looked at a very
large population sample of 1,842,439 which included
340,365 transgendered women. This study demonstrat-
ed that there was a significantly increased rate of MI in
transgendered women compared to cisgendered women
(7.8% vs. 3.1%; p< 0.01) and cisgendered men (7.8%
vs. 5.6%; p< 0.01). However, after adjusting for age,
diabetes mellitus, chronic kidney disease, smoking,
hypertension, hypercholesterolemia, and exercise,
transgendered women only had a significantly
increased risk of MI compared to cisgendered females
(odds ratio [OR], 2.56; 95% CI: 1.78–3.68; p< 0.01)
but not cisgendered men.12
For transgendered men, MI rates were higher when
compared to cisgendered women (7.2% compared to
3.1%; p< 0.010), but there was no difference when
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compared to cisgendered men (7.2% compared to
5.6%; p¼ 0.30). After adjustment for cardiovascular
risk factors, however, the study demonstrated that
transgendered men had an increased risk for MI com-
pared to both cisgendered populations (OR 2.53 95%
CI: 1.14–5.63 compared to cisgendered men; OR
4.90 95% CI: 2.21–10.90 compared to cisgen-
dered women).12
This finding is in contrast with the findings of the
other studies looking at MI in transgendered females
where the MI rate is lower than the cisgendered male63
population and also for transgendered men where stud-
ies have shown the MI rate is either lower or similar to
the cisgendered male population.10,23,63 Although there
was a large study population, the investigators used
self-reporting of trans status to identify the transgen-
dered population in the study rather than a diagnostic
assessment as part of a gender dysphoria assessment
and treatment programme which has been used in the
other reported series. This may mean that the two pop-
ulations differ significantly with regards to access to
gender affirming hormone therapy. Indeed this study
could not comment on whether the individuals were
taking gender affirming hormonal therapy to treat
their gender dysphoria. It may therefore be that case
that taking gender affirming hormonal therapy to treat
gender dysphoria has a positive effect on cardiovascu-
lar outcomes in transgendered people as MI rates are
higher in a self-reported transgendered population
compared to those in a treatment and assess-
ment programme.
This study emphasises the importance of cardiovas-
cular co-morbidities such as smoking, reduced exercise,
diabetes and non-Caucasian ethnic origin, all of which
were seen in higher numbers in the transgen-
dered population.
The balance of evidence appears to support the find-
ing that gender affirming hormonal therapy in trans-
gendered females may reduce MI rate but not to the
level of cisgendered women. In transgendered men, the
risk of MI is higher than the cisgendered female popu-
lation but probably no higher than the cisgendered
male population.
Stroke
Five studies have reported on the incidence of stroke in
the transgendered population. In the Asscheman study,
five people died of stroke and they reported a non-
significant SMR of 1.26 (95% CI: 0.93–1.64).73
Similarly, Wierckx reported an incidence of stroke of
23.4/1000 which was significantly higher than control
men (9.4/1000; p¼ 0.03) but not significantly different
when compared to control females (14.9/1000).44 In the
USA, Meyer reported a reduced stroke incidence in the
transgendered population OR 0.65 (95% CI:
0.43–0.99).11
Two larger studies, however, suggest that the inci-
dence of stroke was increased. Nota et al. reported a
significantly increased rate of stroke in transgendered
females with a SIR 1.8 (95% CI: 1.23–2.56 compared
to cisgendered males) and 2.42 (95% CI: 1.65–3.42
compared to cisgendered females).74 In the Gatahun
paper, however, overall stroke risk was not increased
compared with reference males (HR 1.2 995% CI: 0.9–
17) but increased compared with reference females
(HR 1.9 (95% CI: 1.3–2.6)).10 In a subgroup analysis
looking at those that commenced oestrogen therapy
during follow-up, the incidence of stroke appeared to
increase after six years of treatment compared to both
reference males and reference females.10
These data give conflicting results with regards to
stroke rates in the transgendered female population.
Most of the studies suggest that stroke rates are
between that seen in cisgendered males and cisgendered
females. In contrast, one large cohort study suggests
that increased stroke incidence does not become appar-
ent until six years of exposure.10 However, a moderate-
ly sized study a with follow-up duration of three times
this duration, refuted this finding.22
Thromboembolism
There is strong evidence that oestrogen increases
thromboembolic events in cisgendered women. The
WHI study confirmed that DVT incidence was
increased (HR 1.87 (95% CI: 1.37–2.54) for the
CEEþMPA trial and 1.48 (95% CI: 1.06–2.07) and
pulmonary embolus (HR 1.98 (95% CI: 1.36–2.87).75
In the oestrogen only arm of the trial, this translated to
an extra 7–12 deep vein thromboses/10,000 person-
years.76 A Cochrane review found that hormone
replacement therapy was associated with an increased
risk of venous thromboembolism in all populations of
post-menopausal women: whether HRT started
<10 years post menopause [RR 1.74 (95% CI: 1.11–
2.73)], >10 years post menopause [RR 1.96 (95% CI:
1.37–2.80)] or those with pre-existing cardiovascular
disease [RR 2.02 (95% CI: 1.13–3.62)].77 The increased
risk represents 5–12 additional cases of venous throm-
boembolism (VTE) per 1000 people.77 The increased
risk was largely driven by women on combination hor-
mone therapy.
The route of oestrogen delivery, and type of proges-
tin used in HRT also have an influence on thrombo-
embolic risk. In a case-control study of post-
menopausal women, the rate of VTE was raised in cur-
rent oral oestradiol hormone therapy users,78 (adjusted
OR 4.2 (95% CI: 1.5–11.6) but this was not seen in
transdermal oestrogen (OR 0.9 (95% CI: 0.4–2.1).
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Non-pregnane progestins (nomegestrol acetate and
promegestone) were associated with increased VTE of
OR 3.9 (95% CI: 1.5–10.0) whereas no differences were
noted with micronised progesterone or pregnane deriv-
atives (medroxyprogesterone acetate, dydrogesterone,
medrogestone, chlormadinone acetate and cyproterone
acetate).
In younger women, although stroke and MI risk is
low, that risk is increased by the use of the synthetic
oestrogen ethinylestradiol. The absolute risk is dose
dependant, with oral contraceptives that contained
ethinylestradiol at a dose of 20mg/day increasing the
absolute risk by 0.9–1.7 fold and with those containing
ethinylestradiol at a dose of 30–40mg/day by a factor
of 1.3–2.3.79 As transgendered women usually take
doses 2–5 times higher than this, and safer alternatives
are now available, the use of ethinylestradiol is
best avoided.
Another important cofactor is smoking. Smoking by
women taking the oral contraceptive pill increases the
risk of stroke and DVT.80 The incidence appears to be
dose related, with the higher dose pill (80 lg oestrogen)
having a higher incidence of DVT. The doses of oes-
trogen used in the contraceptive pill are approximately
half those used for feminisation in the transgendered
female population, and so it is strongly recommended
that patients stop smoking prior to commencing oes-
trogen therapy to minimise the risk of DVT. Other
studies of the contraceptive pill have failed to demon-
strate this association, but these studies used combined
contraceptive pills with much lower oestrogen doses
which may explain the different findings.80–82
There have been reports of a possible link between
testosterone replacement therapy use and increased
VTE risk in men;83 however, these studies were
criticised for including data on events such as avascular
necrosis of the femoral head which are not classically
viewed as VTE events. Larger epidemiological studies
have demonstrated that there is no link between testos-
terone therapy and thromboembolism risk, and these
data were summarised in a recent meta-analysis
(OR 1.41 (95% CI: 0.96–2.27)).84
In transgendered women, initial studies suggested
that gender affirming hormone therapy use was associ-
ated with a 45-fold increase risk of VTE when ethiny-
lestradiol and cyproterone acetate was used. This
appeared to be age related as women over 40 years
old had a deep venous thrombosis rate of 12% and
those under 40 only 2.1%.73 By changing to transder-
mal oestrogen after the age of 45 years in transgendered
women, this group reduced the rate of DVT from 12%
to 2.6% in their clinic population.63 The majority of
these incidents occur during the first two years of treat-
ment. There is, however, an on-going risk of 0.4%
per year.63
A recent a meta-analysis of 1767 individuals on oes-
trogen therapy found VTE rates of 0–5% in 10 studies
with variable durations of follow-up.9 The rate of VTE
was not increased in transgendered men.
Since that meta-analysis, two new large trials have
reported VTE rates. Nota et al. have reported signifi-
cantly increased rate of VTE in transgendered women
with a SIR of 4.55 (95% CI: 3.59–5.69 compared to
cisgendered males) and 5.52 (95% CI: 4.36–6.9 com-
pared to cisgendered females).13 There was no increase
in VTE in transgendered men a SIR 0.36 (95% CI:
0.06–1.19 compared to cisgendered males) and 0.41
(95% CI: 0.07–1.37 compared to cisgendered females).
In the large electronic data base cohort study reported
by Getahun et al., the risk for VTE was increased in the
transgendered female population – HR 1.9 (95% CI:
1.4–2.7) compared to reference males and 2.0 (95% CI:
1.4–2.8) compared to reference females.10 This study, in
contrast to all the previously reported studies, report
suggested that VTE risk increases after two years of
oestrogen therapy10 In the earlier literature, the major-
ity of VTE events occurred in the first two years of
treatment,9,13 and further studies are needed to exam-
ine the temporal relationship between thromboembolic
events sand gender affirming hormone therapy in trans-
gendered women. In the Getahun et al. study, again
there was no increase in VTE risk in transgendered
males.10 These new studies suggest a much lower risk
of VTE which is approximately 2-fold higher than the
control populations compared to the previously
reported 20-fold increased risk.
The thromboembolic risk is modulated by several
factors such as the oestrogen type, the route of delivery
and the co-administered androgen-lowering medica-
tions. Ethinylestradiol alters the plasma concentrations
of protein S, C and prothrombin, which results in a
procoagulant haemostatic profile in transgendered
women. Oral ethinylestradiol 100mcg daily in combi-
nation with cyproterone acetate 100mg/day caused a
significant increase in activated protein C (APC) resis-
tance (nAPCsr 1.2 0.8 to 4.1U 1.1); however,
transdermal oestradiol 100mcg twice per week and
cyproterone acetate 100mg or cyproterone acetate
monotherapy had a minor effect (1.3U 0.6 to 2.0U
 2.0 and 1.4 0.6 to 1.8 0.9, respectively).85
Ethinylestradiol and cyproterone acetate also
decreased the coagulation inhibitor Protein S. These
changes were not observed when either transdermal
oestrogen or oral oestrogen valerate was used.85
There were no thromboembolic events seen in either
group, but this was a short-term study. The presump-
tion from this study was that the route of administra-
tion of oestrogen was important but other studies have
challenged this view, suggesting the type of oestrogen
and not route of administration may be more
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important. A study demonstrated that the incidence of
VTE in a population of 330 transwomen was 0.6% for
those treated with oral oestradiol in doses of up to
10mg daily but the incidence of VTE was eight-fold
higher in those treated with CEE. These data would
support the hypothesis that oestrogen type not route
of administration has more impact on DVT rate in
transwomen.86 This has also been recognised in contra-
ceptive practice where the prothrombotic effect of ethi-
nylestradiol has been ascribed to its molecular structure
rather than to the first-pass liver metabolism creating
thrombogenic oestrogen breakdown products.87
Hormonal factors in cardiovascular
disease in transgendered people
We know from long-term outcome studies that the use
of ethinylestradiol in transwomen is associated with
increased cardiovascular risk (adjusted OR 3.64 (95%
CI: 1052–8.73) and this risk is not seen in past users of
ethinylestradiol, 17b-oestradiol preparations or conju-
gated equine oestrogen (CEE).22 The problem with the
meta-analyses so far is that few of the transgendered
women were treated with 17b-oestradiol, the majority
were treated with either ethinylestradiol or CEE, and
only 7% were on 17b-oestradiol and GnRH analogues.
This is an area where further research is needed to
characterise the effects of 17b-oestradiol preparations
rather than ethinylestradiol or CEE on lipid
parameters.7
In modern practice, the majority of clinics interna-
tionally have moved to using 17b-oestradiol rather
than other oestrogen preparations when providing
gender affirming hormonal therapy for transgendered
women and this may have contributed to the reduced
VTE risk observed in the newer larger studies. This
change in clinical practice, however, acts as a con-
founding factor because the long-term follow-up stud-
ies include individuals treated with both types of
oestrogen regimen13,21,22 making the interpretation of
long-term data difficult in this population.
Smoking is also a significant confounder in these
studies. We know from the combined contraceptive
pill studies that the incidence of VTE is increased in
smokers by approximately two-fold, and smoking in
combination with obesity increases this risk to nine-
fold.88 An important feature of the protocol used in
the largest UK clinics is that the client must stop smok-
ing in order to receive high-dose oestrogen,89 which is
an attempt to reduce the VTE risk of this patient pop-
ulation. The incidence of smoking in the recent Dutch
long-term study is estimated at 43–46%13 whereas the
incidence of smoking at the time of a cardiovascular
event in the Getahun et al. report was 20%.10
As smoking is a strong cofactor in both VTE and car-
diovascular events in transgendered people,23 these dif-
ferent levels of tobacco use across cohorts may have a
significant impact on the rates of cardiovascular events
making the interpretation of results difficult. In UK
practice, individuals strongly are encouraged to cease
smoking before hormone therapy is initiated.89
Finally, the method used for testosterone suppres-
sion may have an influence on the rate of cardiovascu-
lar disease. In Europe, cyproterone acetate is the
mainstay of androgen suppression. This antiandrogenic
progestin may increase the risk of thromboembolism
when given in combination with oestrogen. We know
from the cisgendered female population that oestrogen
progestin HRT is more thrombogenic than oestrogen
alone HRT.75
In the UK, GnRH analogues form the mainstay of
androgen suppression.90 In Europe because of the
expense of these medications, it is more usual to use
cyproterone acetate for androgen suppression. One
study has made a direct comparison between cyproter-
one acetate and leuprolide for androgen suppression in
combination with transdermal 17b-oestradiol.
Leuprolide was equally effective at inducing androgen
suppression but it was less likely to induce hyperpro-
lactinaemia. More interestingly 17b-oestradiol and
leuprolide therapy increased HDL cholesterol (þ0.2
 0.5mmol/L) whereas cyproterone acetate and
17b-oestradiol therapy decreased HDL-cholesterol
(0.2 0.3mmol/L).91 This may be important in the
development of cardiovascular disease which may
alter the rates.
In transgendered men, it is interesting that adverse
effects of androgens on lipid profile do not appear to
translate into an alteration in cardiovascular risk.
There is no increase in cardiovascular mortality in
testosterone-treated transgendered men; indeed the
MI rate is between one-third expected in the cisgen-
dered male population63 and expected male gender
population norms.13 These findings have been con-
firmed in long-term follow-up studies where the
standard mortality ratio for transmen is not different
from the general population.22 These data suggest that
cardiovascular risk factors have less of an impact on
cardiovascular disease in transgendered men compared
to cisgendered men. The mechanism for this would be
interesting to explore in future studies looking at the
impact of the protective oestrogenic environment in
early life on future cardiovascular risk.
Conclusion
Current evidence suggests that hormonal therapy for
transgendered women decreases or is neutral regarding
MI. There is an increased incidence of VTE, but newer
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studies suggest that the risk is significantly lower than
previously described. The studies available looking at
more modern regimens are, however, scarce and cur-
rently have short-term follow-up duration. Therefore,
we do not yet know whether these treatment regimens
will improve cardiovascular risk. Stroke risk may be
increased and further studies are required to clarify
the long-term cardiovascular risks of gender affirming
hormonal therapy in transgendered women.
For transgendered men, there appears to be an
adverse effect on lipid parameters, but this does not
translate into an increased risk of cardiovascular dis-
ease. The younger age of transgendered men in the
studies so far may mean that a longer follow-up is
needed to assess whether there is truly an increased
cardiovascular risk.
In all transgendered people, cardiovascular risk
factor interventions such as smoking cessation, weight
management and treatment of co-morbid conditions
are important in optimising cardiovascular health.
The effects of gender affirming hormonal therapy on
transgendered people’s cardiovascular health are diffi-
cult to interpret due to the variety of hormone regimens
used, the relative brevity of the periods of observation
and the influence of confounding factors. There is still
need for further research in this area.
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